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Attention-Deficit/Hyperactivity Disorder (ADHD) has a very high heritability (0.8), suggesting
that about 80% of phenotypic variance is due to genetic factors. We used the integration of
statistical and functional approaches to discover a novel gene that contributes to ADHD. For
our statistical approach, we started with a linkage study based on large multigenerational
families in a population isolate, followed by fine mapping of targeted regions using a family-
based design. Family- and population-based association studies in five samples from
disparate regions of the world were used for replication. Brain imaging studies were
performed to evaluate gene function. The linkage study discovered a genome region harbored
in the Latrophilin 3 gene (LPHN3). In the world-wide samples (total n=6360, with 2627 ADHD
cases and 2531 controls) statistical association of LPHN3 and ADHD was confirmed.
Functional studies revealed that LPHN3 variants are expressed in key brain regions related
to attention and activity, affect metabolism in neural circuits implicated in ADHD, and are
associated with response to stimulant medication. Linkage and replicated association of
ADHD with a novel non-candidate gene (LPHN3) provide new insights into the genetics,
neurobiology, and treatment of ADHD.
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Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is
the most common behavioral disorder of childhood,
with a high prevalence,1 poor outcome,2 substantial
costs3 and comorbidity with other behavioral and
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emotional disorders.4 Genetic factors are strongly
implicated in the etiology of ADHD.5 More than a
decade ago, candidate gene association studies iden-
tified two genes with small effects,6,7 and these
associations have been replicated.8 Many additional
candidate genes have been evaluated, and some initial
reports of association with ADHD have emerged, but
these have not been replicated.9 Several unbiased
genome-wide studies have been conducted and
reported, but none has identified additional genes
that contribute to the genetic basis of ADHD. Follow-
ing the suggestion of Risch and Merikangas,10 the
genome-wide association study (GWAS) approach has
been used, but this did not produce a significant effect
or even confirmed the replicated associations with the
DRD4 and DAT genes.11
The lack of success of GWAS to discover new genes
related to ADHD is not unexpected. As for others
disorders and traits with high heritability (such as
height), the identified associated genes account
for 5–10% of the estimated heritability, creating a
mystery of ‘dark’ or unexplained heritability.12 It has
been assumed that many additional genes with small
independent effects likely exist but have not been
discovered. The integration of statistical and func-
tional approaches has been recommended to uncover
the ‘dark matter’ and begin to account for the
heritability of common disorders.13
We identified large and multigenerational families
from a genetic isolate, the Paisa population in
Antioquia, Colombia.4,14 The prevalence of ADHD is
high and often comorbid with disruptive behaviors
in the Paisa.4 This makes the Paisa population well-
suited for a linkage study to discover new genes that
contribute to the etiology of ADHD. The initial study
in our program of research evaluated ADHD symp-
toms in informative families ascertained in the Paisa
and concluded that they would provide exceptionally
good power to detect linkage even in the presence of
heterogeneity.14 A genome-wide linkage study15 of 16
informative families with 433 individuals reported
significant linkage of ADHD to a region on chromo-
some 4q13.2.14–16 Fine mapping applied to nine
linked families sharpened the linkage signal, dis-
closed new meiotic recombination events in ADHD-
affected individuals, and in conjunction with the
LOD-1 supported interval criterion narrowed the
minimal critical region down to B20 Mb (Table 1,
Supplementary information).15 Here, we report the
next steps in this research program, which were
designed to identify the gene responsible for the
ADHD linkage signal and to elucidate its functional
properties.
Materials and methods
Subjects
Detailed descriptions of clinical and demographic
features of the Paisa sample for the linkage study have
been published elsewhere.4 We used 18 extended
families with 433 individuals, and 137 nuclear T
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families with 527 individuals. The samples used for
replication were ascertained from disparate regions
of the world, namely from the United States
(two independent samples, US1,17 and US218),
Germany,19 Norway20 and Spain21 (see Table 1). A
total of 1410 families with 6360 individuals were
evaluated. Approvals to conduct the study (Protocol
no. 00-HG-0058) were obtained from the Institutional
Review Boards of the National Human Genome
Research Institute and those of the collaborating
institutions.
Genotyping
DNA from the Colombian, US1, US2, German and
Spanish samples was prepared from peripheral-blood
specimens. DNA from the Norwegian sample was
extracted either from whole blood or from saliva.
The Illumina genotyping service was used for geno-
typing, except for the sample from Norway that was
genotyped using Sequenom’s MassARRAY iPLEX
System (additional information in Supplementary
information).
Screening of the minimal critical region in 4q13.2
Fine scale mapping with a resolution of B68 kb
(a third of the minimum distance able to provide full
coverage in the Paisa population22) was conducted in
the Paisa multigenerational sample of 18 families (433
individuals) and in the ADHD sample of 137 nuclear
families (527 individuals) ascertained from the same
genetic isolate. Areas of interest that are gene rich or
carry potential candidates were covered at a higher
density (Figure 1, Supplementary information). An
empirical linkage disequilibrium map, built using
control individuals, showed full coverage of the
entire region and excluded uncovered gaps
(Figure 2, Supplementary information).
Screening for sequence variations and SNP tagging
The finding that a shared ADHD susceptibility
haplotype was embedded within the Latrophilin 3
(LPHN3) gene, and the absence of other known genes
in the region, prompted further pursuit of the
relationship between LPHN3 variants and suscept-
ibility to ADHD. Hence, the entire coding region of
LPHN3 was sequenced in eight individuals carrying
two (n= 4), one (n= 2), or zero (n= 2) copies of the
susceptibility haplotype variants. In addition, 46
individuals from different families showing either
nominal, suggestive or significant signals of linkage at
the region were also sequenced using Surveyor
(Transgenomics, Omaha, NE, USA). Furthermore,
139 unrelated patients diagnosed with ADHD from
the United States and 52 commercially available
normal controls were also studied. For the US and
control samples, mutation detection was performed
by PCR-based denaturing High Performance Liquid
Chromatography analysis followed by direct bi-direc-
tional sequencing (variants identified are presented in
Figure 3a, Supplementary information). Additional
SNP selection and tagging employed a quality-based
filter, a second population information-based filter
(MAF, linkage disequilibrium blocks), and a third
biological significance-based filter (coding, expres-
sion modulating, splicing modulating and assessing
evolutionary conservation) (Figures 3b–e, Supple-
mentary information). Databases used for the selec-
tion were SNPdb (NCBI) and UCSC genome browser.
Quality filtering was based on the information
available through the SNP track of the UCSC genome
browser and by using AB SNPbrowser 3.0. Custo-
mized LD blocks were defined using AB SNPbrowser
3.0 and Haploview. Biological relevance was anno-
tated on the UCSC genome browser with data
available from UCSC (genome browser), NCBI (Entrez)
and EBI (Ensembl). Conservation was based on the
MAF 8X conservation track (courtesy of Elliott
Margulies, NHGRI, NIH) and Exact Plus software
(courtesy of Anthony Antonellis, NHGRI, NIH). The
US1, the German and the Paisa sample were geno-
typed for the same set of SNPs (n= 120) (Figure 3e and
Supplementary Table 5, Supplementary information).
The sample from Norway was genotyped using a two-
stage design: 60 markers were first genotyped in 343
adult Norwegian ADHD patients and 336 controls
(Supplementary Table 5, Supplementary infor-
mation). All SNPs with a nominal P-value < 0.15
(7 markers) were then included in a second round of
genotyping using a new set of 107 cases and 249
controls. The US2 sample was genotyped for 77 SNP
markers, and the Spanish sample was genotyped for
45 SNP markers (Supplementary Table 5, Supple-
mentary information).
Genetic statistical analyses
Family-based association tests were applied by
comparing allele frequencies for transmitted and
untransmitted alleles using PLINK.23 Parameters for
excluding markers from analyses include a MAF less
than or equal to 0.05, Hardy–Weinberg equilibrium
deviations with P-values < 0.0001, and a minimum
genotype of 90%. Mendelian errors were checked
using PEDSTATS.24 Families with excessive Mende-
lian errors were excluded. SNPs with > 2 Mendelian
errors also were excluded. We tested unaffected
siblings looking for overtransmission bias caused by
evolutionary forces, such as selection in utero against
deleterious mutations, meiotic drive and maternal–
fetal incompatibility,25 but found no significant
overtransmission for any single marker or for any
haplotype in the entire region. Linkage disequili-
brium via cladistic analysis was performed using
CLADH26 with a Bonferroni-adjusted threshold global
permutation P-value (10 000 permutations). With
CLADH,26 clades of haplotypes are tested for associa-
tion with disease, exploiting the expected similarity
of chromosomes with recent shared ancestry in the
regions flanking the disease gene. We selected only
one affected case from each pedigree. As controls,
haplotypes of unrelated individuals without ADHD
were chosen. To abrogate confounding from poten-
tially undetected genotyping errors and the presence
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of meiotic drift when the risk variants are the most
common, we tested additional SNP markers harbored
in the LPHN3 gene, including those new variants
disclosed by our sequencing analyses plus other
potentially functional and phylogenetically con-
served SNP variants (Figures 3a–e, in Supplementary
information). For haplotype analyses both uncertain
and infrequent variants ( < 1%) were excluded. To
infer genotypes not assessed homogeneously in the
samples, we performed in silico genotyping as
implemented in IMPUTE.27 The Hapmap CEPH
sample was used as our comparison set of phased
haplotypes. All genotypes inferred with > 90%
genotype probability were retained. Odds ratios
in family-based samples were estimated by the
number of transmitted target alleles/the number of
LPHN3: a new ADHD susceptibility gene
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untransmitted alleles in heterozygous parents only.28
Family-based odds ratios from the TDT tests in the
Paisa, US1, US2, German, and Spanish samples were
combined with the case–control odds ratio from
the Norwegian sample using a meta-analytical ap-
proach.29 The random-effects method30 was used
when significant heterogeneity was present and the
fixed-effects method otherwise.31
Expression of LPHN3 in human brain
We studied the expression of identified genes in
northern blots (Human Brain MTN Blots II and V)
purchased from BD Biosciences (Palo Alto, CA, USA)
with the gene probe synthesized based upon its cDNA
sequence at Invitrogen (Carlsbad, CA, USA) and
analyzed in brain tissues from amygdala, caudate
nucleus, cerebellum, orbital frontal cortex, pontine
Paisa
USA1
USA2
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Norway
Spain
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Summary
Paisa
USA1
USA2
Germany
Norway
Spain
Summary
Fixed-Effects Meta-Analysis for rs1947274
Fixed-Effects Meta-Analysis for rs2345039
St
ud
y 
Re
fe
re
nc
e
St
ud
y 
Re
fe
re
nc
e
St
ud
y 
Re
fe
re
nc
e
Odds ratio
-
lo
g 1
0(p
va
lue
)
Fixed-Effects Meta-Analysis for rs6551665
Position
61.9 62.1 62.3 62.5 62.6 62.8 63.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Interval Association Analysis
rs6551665
rs1947274
rs2345039
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Odds ratio
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Odds ratio
0.0 0.5 1.0 1.5 2.0 2.5
Figure 2 (a) Location at the LPHN3 gene of the three markers, rs6551665, rs1947274 and rs2345039, reaching significance at
the meta-analysis after 10 000 permutations. (b) Forest plot of odds ratios showing fixed effect results for rs6551665
(OR = 1.23, 95% CI 1.09–1.137, P= 3.46 104), rs1947274 (OR = 1.23, 95% CI 1.09–1.38, P= 5.41 104), and rs2345039
(OR = 1.21, 95% CI 1.08–1.35, P= 8.97 104), through populations.
Figure 1 (a) Results for association and linkage disequilibrium analyses on extended and nuclear ADHD families of the
Paisa community (Antioquia, Colombia). On the x axis are base-pair coordinates (60–80 Mb) at 4q13.2; on the y axis, -log (p).
Dots represent the distribution of the Z-statistic (single marker-based) for extended families: Black dots represent nuclear
families; Red dots, the pooled families. The continuous lines of different colors represent the distribution of absolute values
for -log (p) after testing for linkage disequilibrium using a permutation test on haplotype windows of different sizes. This
level of significance was robust with respect to different haplotype windows (from 3 to 7 markers) and to correct for multiple
comparisons. The Bonferroni-adjusted threshold P-value is represented as a red line at log(p) = 4.25. A significant peak
of association is located at the region between coordinates 62 and 63 Mb. (b) Annotated structure of LPHN3 showing exons
1–24, the major protein structural domains, and the area of the susceptibility haplotype. The haplotype (in red) covers the
olfactomedin domain, part of the mucin-like stalk, the hormone receptor domain, the G-Protein Coupled Receptor (GPCR)
Proteolytic Site—domain and transmembrane helices 1–6 of the seven transmembrane spanning region. The isoforms
represent the three splice site variants of LPHN3. (c) Haplotype variants transmitted in affected individuals from families
with significant linkage of ADHD to 4q13.2. Comparison of these variants is carried out against F9 (row 1), the family
providing the most to the linkage signal as published in Arcos-Burgos et al.15 The shared region in orange exactly
corresponds to the region mapped by family-based genetic association analyses. (d) Structure of LPHN3 with the protein
domains that correlate with the ADHD susceptibility haplotype in red.
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nuclei, cingulate gyrus, occipital cortex and thalamus.
Probes were labeled with g-32P-ATP (GE Healthcare,
North Arlington Heights, IL, USA) by T4 polynucleotide
kinase (Invitrogen) and purified by Qiaquick Nucleotide
Removal Kit (Qiagen, Valencia, CA, USA). Membranes
were prehybridized with ExpressHyb (BD Biosciences)
for 1h at 42 1C and hybridized with labeled probes for
3 h at 42 1C. After hybridization, membranes were
stringently washed and exposed on Kodak film at
70 1C for 10 days. Human brain tissue for in situ
hybridization was obtained from the Brain and Tissue
Bank for Developmental Disorders at the University of
Maryland, Baltimore, MD, USA from male accident
victims deceased at 2, 5, 8 and 30 years of age. Though
reported as healthy normal individuals, there was no
information regarding the mental health status.
A b-actin probe was used for normalization. The
antisense probe for LPHN3, a 362-bp amplicon within
the final coding exon, was subcloned into Bluescript
KS- (Stragene, San Diego, CA, USA) and synthesized
LPHN3
β-actin
1 7 9 10 11 12 13 142 6
SenseAntisense ControlAntibody
6.2kb
2.0kb
8543
Figure 3 (A) Northern blots reveal expression of LPHN3 mRNA in different regions of the human brain. Lane 1, Amygdala;
Lane 2, Caudate Nucleus; Lane 3, Corpus Callosum; Lane 4, Hippocampus; Lane 5, Whole Brain Extract; Lane 6, Thalamus;
Lane 7, Cerebellum; Lane 8, Cerebral Cortex; Lane 9, Medulla; Lane 10, Spinal Cord; Lane 11, Occipital Pole; Lane 12, Frontal
Lobe; Lane 13, Temporal Lobe; and Lane 14, Putamen. (B) In situ hybridization of human brain tissue from a 2 year old
reveals positive cytoplasmic signal with LPHN3 antisense. LPHN3 sense provided a negative control. Selected positive
neurons are marked by arrows. (a, b), Amygdala; (c, d), Caudate Nucleus; (e, f), Pontine Nuclei; (g, h), Cerebellum
(c) Immunohistochemistry of human brain tissue from a 2 year old reveals positive cytoplasmic immunoreactivity with
LPHN3 antibody. Primary LPHN3 antibody was omitted for negative control. Selected positive neurons are marked by arrows.
(a, b), Amygdala; (c, d), Caudate Nucleus; (e, f), Pontine Nucleus; (g, h), Cerebellum. Immunoreactive Purkinje cells are
marked by arrows.
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using a T3 primer. Expression in fetal brain was more
pronounced than in whole postnatal brain. Fibro-
blasts and testes also showed notable expression.
Minimal expression was detected in thymus, lung,
prostate, ovaries, heart, pancreas, liver and kidney.
No expression could be detected in cDNAs from
leukocytes, spleen, skeletal muscle, colon, small
intestine and placenta (data not shown). The in situ
hybridization experiments were performed at Histo-
serv (Germantown, MD, USA). In addition, a panel of
normal human pooled cDNAs (BD Biosciences,
Clontech, CA, USA) revealed robust expression of a
single 3.7 Kb LPHN3 amplicon (primers covering the
entire open reading frame) in cerebellum, cerebral
cortex, thalamus, amygdala, substantia nigra, hippo-
campus, spinal cord and retina (data not shown).
For immunohistochemical analyses serial sections
were taken from paraffin-embedded tissue blocks
for immunohistochemical examinations. For antigen
retrieval, sections were treated with 0.01 M sodium
citrate buffer (pH 6.0) at 100 1C for 10 min. Sections
were cooled at room temperature for 20 min and
washed three times in PBS. Sections were then
quenched for 20 min in a solution of 3 ml H2O2 and
180 ml methanol. After three washes in PBS, sections
were incubated in 10% horse serum for 1 h. The
LPHN3 primary antibody (1:500, Novus Biologicals,
Littleton, CO, USA) was diluted in 2% horse serum,
and the sections were incubated in a humidified
chamber at 4 1C overnight. The sections were incu-
bated with secondary antibody for 1 h followed by
avidin–biotin complex incubation for 1 h and visua-
lization with diaminobenzidine. The sections were
counterstained with Mayer’s hematoxylin for 10 min,
dehydrated by graded ethanol washes of 95 and
100%, and rinsed in xylene before being mounted.
Proton magnetic resonance spectroscopy (1H-MRS)
We explored potential differences between carriers
and non-carriers of the susceptibility haplotype with
proton magnetic resonance spectroscopy (1H-MRS) to
measure neuronal number or viability32 as assessed by
the ratio of N-acetylaspartate (NAA) to creatine (Cr).
Brain regions that define the frontal–striatal–cerebel-
lar circuit known to be dysfunctional in ADHD33–36
were targeted. To obtain measures of metabolic brain
activity using 1H-MRS, T2-weighted high resolution
anatomic images were obtained in the axial plane
(TE = 103 ms, TR = 5910 ms, 3 mm slice thickness
and 5:27 min:s imaging time). Axial images were
oriented parallel to the orbitomeatal anatomical
reference plane. The T2-weighted images were used
to guide multi-voxel MR spectroscopy volume selec-
tion. The 2D chemical shift imaging (CSI)
point-resolved spectroscopic sequence (PRESS) tech-
nique (TE = 30 ms, TR = 1500 ms, NEX = 3, resolution
10 mm10 mm10 mm, acquisition time = 6:05) was
localized in the inferior vermis using the anatomical
reference images. Three-dimensional CSI PRESS
sequence (TE = 30 ms, TR = 1500 ms, NEX = 3, resolu-
tion 13.3 mm13.3 mm 13.8 mm, acquisition
time = 10:23) explored the center of the brain includ-
ing the striatum, thalamus and the cingulate gyrus
relative to anatomic images. Saturation bands around
the 2D and 3D Volumes of Interest were used to
prevent contamination of the spectra from subcuta-
neous fat signal. All MR data were obtained on a 1.5 T
Symphony Master Class Siemens Clinical Imaging
System using an 8 channel head array coil. The
spectra were transferred offline to be processed
automatically using the LCModel.37 For this initial
analysis, we focused on the ratio NAA to Cr within
each spectral voxel.38 Average data from voxels
covering the left and right striatum (3–4 voxels),
lateral (2 voxels) and medial (2 voxels) aspects of the
thalamus, anterior (1 voxel), medial (1 voxel) and
posterior (1 voxel) cingulate gyrus, and inferior vermis
(2 voxels) were analyzed. Voxels containing cerebrosp-
inal fluid were excluded from analyses. Criteria for
acceptable reliability were those recommended by the
LCModel provider. The imaged participants were
neither sedated nor receiving medications for treatment
of ADHD. Total scanning duration was 45 min. Absolute
metabolite quantification was not attempted because of
the requirement for markedly increased data acquisition
time, which is particularly problematic for patients with
ADHD. The general linear model was used to provide
exploratory analyses to evaluate between-group differ-
ences with an uncorrected two-tailed a-level of 0.05.
Pharmacogenetic Study
An effectiveness evaluation of medication response
was conducted in 240 children from the US1 sample17
rated on and off stimulant medication on the Strengths
and Weaknesses of ADHD-Symptoms and Normal-
Behavior (SWAN) Scale.39 By truncating the SWAN
ratings, the standard ratings of symptom severity (just
weaknesses) can be captured. The SWAN scale differs
from other scales in its definition of items and in its
scoring system, which give a closer approximation to a
normal distribution for each item and of summary
scores of overall ADHD and its two domains (Inatten-
tion and Hyperactivity–Impulsivity) in the general
population than does any other ADHD scale that
evaluates psychopathology.39 In addition, the heritabil-
ity of the SWAN scale has been shown.39 Consistency
scores were estimated for each interview, using a scale
from 1 (unreliable) to 10 (fully reliable), according to
the concordance between two questions. A full
description of ascertainment and clinical diagnostic
strategies of the US1 sample is presented elsewhere.17
We used statistical methods to identify clusters to
define responders and non-responders using Latent
Class Cluster Analysis.40 Latent Class Cluster Analysis
models containing 1 through 12 classes were fitted to
the data using Latent GOLD 3.0.1 software (Statistical
Innovations, Belmont, MA, USA). Latent GOLD uses
both expectation/maximization (EM) and Newton–
Raphson algorithms to find the maximum likelihood
of each model after estimating model parameters.40–42
To avoid ending up with local solutions (a well-
known problem in LCA), we used multiple sets of
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starting values as automatically implemented in
Latent GOLD. Because we were dealing with sparse
contingency tables, we estimated P-values associated
with L2 statistics by means of parametric bootstrap
(500 replicates) rather than relying on asymptotic P-
values. As covariates for the model, we used gender,
ADHD medication usage and age. Age was included in
our models as a continuous variable, as a categorical
variable based on deciles (that is, 1–10, 10–20, etc.),
and as a categorical variable using the age ranges we
used previously (that is, children are between 4 and 11
years; adolescents 12–17; and adults are 18 years or
older).17 Our final models used the latter approach
because it resulted in smaller bivariate residuals.
Initially, we did not consider the presence of
interactions between variables and the basic assump-
tion of local independence of the standard latent class
model was supported. Next, we relaxed the local
independence assumption by allowing for interac-
tions between variables, as well as for direct effects of
covariates on variables.40,42,43 Latent GOLD calculates
bivariate variable–variable and variable–covariate
residuals that can be used to detect which pairs of
observed variables are more strongly related. There-
fore, bivariate residuals greater than 3.84 were
included iteratively for each model to identify
significant correlations between the associated vari-
able–variable and variable–covariate pairs inside each
class (for one d.f., bivariate residuals greater than 3.84
indicate statistical significance at the 0.05 level). As
implemented in Latent GOLD, individuals are as-
signed posterior membership probabilities for belong-
ing to each cluster based on their symptom profiles.
Cases are then assigned to the cluster for which the
posterior membership probability is highest. Based on
this assignment, we compared cluster membership to
our DSM-IV-based best-estimate clinical diagnoses of
ADHD. Effects of covariates like dose, gender and age
were controlled. We formed clusters based on two
procedures. First, we used the traditional procedure
based on ratings from just the OFF medication
condition, which generated 7 clusters (subgroups).
Then, we re-established clusters based on parent
ratings from the ON medication condition, which
identified 6 clusters. Then, by estimating conditional
LCC probabilities of transition, we were able to define
probabilities of effectiveness of stimulant treatment in
ADHD. Significance of the transition between clusters
was empirically obtained using 100 000 simulations
assuming the multinomial distribution. Second, we
used parent ratings from both the ON and OFF
medication conditions to establish clusters. Based
on these two approaches we designated each cluster
of ADHD patients to being either responder or not
responder to stimulant treatment.
The response trait was tested for association to
the candidate SNPs using the TDT. Frequencies and
proportions were estimated for categorical variables.
Means and standard deviations were calculated for
continuous variables. Categorical variables were
compared using the w2-test. Continuous variables
fitting both normality and homogeneity of variances
were compared using the t-test for independent
samples; otherwise they were tested using the non-
parametric Mann–Whitney’s U-test. Normality and
variance homogeneity were tested with the Shapiro–
Wilks and the Bartlett tests, respectively. Cohen’s d-
effect size of non-overlapped data was estimated for
all variables using pooled variances.
Results
Gene discovery
The next stage of the positional cloning method of our
research program was based on the analysis of fine
mapping. Partitioned and joint family-based associa-
tion,44 marker,45 and haplotype-based26 analyses re-
vealed, after correction by multiple comparisons, a
significant area of association with ADHD, delimited
by the SNP markers rs1901223 and rs1355368
(P= 3.1103, marker based; P= 2.7 105, haplotype
based) (Figure 1a) (Supplementary Tables 2, 3, and 4).
The region of association is located on chromosome 4
at 62.4–62.7 Mb (UCSC coordinates) within the
LPHN3 gene encompassing exons 4 through 19
(Figure 1b). Empirical analysis of meiotic events in
ADHD-affected subjects from linked families pointed
to the same LPHN3 gene region (Figure 1c). The
ADHD region of association involves sequences
coding for the olfactomedin, hormone receptor, the
G-protein-coupled receptor proteolytic site, and
transmembrane domains of LPHN3 (Figure 1d), and
contains the bulk of the variability conferred by
LPHN3 splice isoforms (Figure 1b).
Figure 2a shows three markers that passed a test of
heterogeneity and were significant after adjusting for
multiple tests: rs6551665 (OR = 1.23, 95% CI 1.09–1.37,
P= 3.46104) and rs1947274 (OR = 1.23, 95% CI
1.09–1.38, P= 5.41 104) and rs2345039 (OR= 1.21,
95% CI 1.08–1.35, P= 8.97104) (Table 2, Figure 2b).
Marker rs6551665 was genotyped in all of the samples.
In the Hapmap CEPH sample, the Paisa, and the US1
sample, these three markers belong to a common LD
block. Despite our conservative approach (the correc-
tion of statistical significance due to multiple testing for
this gene), P-values reported here have strongly over-
come estimated threshold values.
Screening for sequence variations
We sequenced all LPHN3 exons and intron–exon
boundaries and identified two SNPs of potential
significance for the expression profile of LPHN3. Both
SNPs are in the haplotype block associated with ADHD
and are located at splice sites. One SNP, rs1397548
(G > A; major allele in Caucasians: G), is located at the
last base of the last codon of exon 15. Even though this
base change itself does not change the translation
(synonymous change, that is, p.P937P), it may affect
proper splicing. This splice site variant decreases the
splice site score from 93 to 80, suggesting a decrease of
the recognition of this altered splice site leading to a
skipping of exon 15.46 The deletion of exon 15,
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containing 210 bases, is an in-frame deletion and would
generate a shortened protein with potentially altered
functions. The other SNP, rs2305339 (A > G; major allele
in all populations studied so far: A), is located at the 4
position of intron 10. Sequence variations at this
position could also cause aberrant splicing, but are less
well-defined. Regular splicing and some aberrant
splicing may result, with generation of a regular full
length product and potentially an mRNA with a
deletion of exon 11. A deletion of exon 11, containing
184 bases, is out of frame and would create a premature
stop codon at amino acid position 643. Thus, this
variant could generate a certain degree of haploinsuffi-
ciency, but importantly it does not predict a complete
loss of function for this protein. While preliminary,
corroborating the functional effect of these variants will
require additional studies.
Expression of LPHN3
Northern blot analysis showed significant expression
of LPHN3 mRNA in amygdala, caudate nucleus,
cerebellum and cerebral cortex (Figure 3A, lanes 1,
2, 7, 8). Lower expression was detected in corpus
callosum, hippocampus, whole brain extract, occipi-
tal pole, frontal lobe, temporal lobe, and putamen
(Figure 3A, lanes 3, 4, 5, 11, 12, 13, 14). No expression
was detected in thalamus, medulla and spinal cord
(Figure 3A, lanes 6, 9, 10). LPHN3 expression
examined by in situ hybridization of formalin-fixed
tissues of brain regions from humans of different ages
showed a strong cytoplasmic signal in neurons of the
amygdala, caudate nucleus, pontine nucleus and in
Purkinje cells of the cerebellum at all ages tested, that
is, at 2, 5, 8 and 30 years; tissues of a 2 year old are
shown in Figure 3B. Involvement of the prefrontal
cortex, cerebellum, amygdala47 and temporal lobes
has been implicated in ADHD.48 Weak cytoplasmic
signals for LPHN3 were observed in a subset of
cingulate gyrus neurons in the 2- and 5 year olds,
but not in the 8- and 30 year olds, and in indusium
griseum neurons in the 2 year old (data not shown).
Areas of the brain that revealed LPHN3 expression
by in situ hybridization were also consistently
immunoreactive using anti-LPHN3 antibody
(Figure 3C).
Brain chemistry
For 1H-MRS we chose target regions (striatum,
cingulate gyrus, and cerebellar vermis) based on
previous evidence of anatomic abnormalities and
added a region that has been difficult to quantify
volumetrically (the medial and lateral thalamus48).
The voxel placement is shown in Figure 4A. MRS was
performed on a total of 33 individuals selected to
differ on the haplotype defined by variants of SNPs
rs6551665, rs1947274 and rs2345039, with 15 individ-
uals (ADHD-affected = 13, ADHD-unaffected = 2) hav-
ing the risk haplotype, 10 individuals (ADHD-
affected = 1, ADHD-unaffected = 9) with the protective
haplotype, and eight individuals (all unaffected) withT
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haplotype variants differing from the susceptibility
and protective haplotype variants. Across all individ-
uals carrying the haplotype with susceptibility var-
iants, NAA/Cr was significantly decreased in the left
lateral thalamus (P< 0.01), left medial thalamus
(P< 0.05), and the right striatum (P< 0.05), and
significantly increased in the inferior–posterior cere-
bellar vermis49 (P< 0.05). To control for ADHD status,
we examined the effect of the number of copies of
haplotypes containing susceptibility and protective
variants on the NAA/Cr ratio. The NAA/Cr ratio
increased monotonically in the right medial and
lateral thalamus in relation to the number of copies
of the protective haplotype (Figure 4B). Carriers of
two copies of the susceptibility haplotype had the
lowest levels of NAA/Cr; the ratio increased in a
dosage-dependent fashion, reaching the highest levels
in individuals with two copies of the protective
haplotype and in controls, that is, those individuals
with variants different from the susceptibility and
protective haplotypes (P< 0.05).
Response to stimulant medication
ADHD individuals belonging to clusters 2, 4, 6 and
7 in Figure 5a were defined as responders to
stimulant treatment. No significant difference was
found between responders and non-responders for
demographic or clinical variables such as sex, age,
GLM term
Intercept
Sex
log(Age)
Haplotype (Yes: 1; No: 0)
ADHD Status (Yes: 1, No: 0)
Sex*log(Age)
Sex*Haplotype
log(Age)*Haplotype
Sex*log(Age)*Haplotype
Estimate
1.4850
-0.1548
-0.0718
6.4989
0.0556
-0.0001
-6.6810
-1.8001
1.8547
Std. Error
0.2846
0.3795
0.0852
2.4889
0.0895
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0.6638
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Figure 4 (A) 1H-MRS brain imaging. Turquoise squares show voxel selection at different brain structures for which 1H-MRS
ratios were acquired. (a) right and left striatum (3–4 voxels); (b), right and left lateral (2 voxels, blue) and medial (2 voxels)
thalamus; (c and d), right and left anterior (1 voxel) and posterior (1 voxel) cingulate gyrus; e, right and left mid-cingulate
gyrus (1 voxel); (f and g), posterior–inferior vermis (2 voxels). (B). Plots of marginal means for levels of NAA/Cr at the right
medial and lateral thalamus (y axis), showing an inverse relationship between the NAA/Cr ratio and the number of copies of
the haplotype carrying variants of susceptibility of the markers rs6551665, rs1947274 and rs2345039. On the x axis are points
for 2S (two copies of the susceptibility haplotype), 1S (one copy of the susceptibility haplotype), 1P (one copy of the
protective haplotype), 2P (two copies of the protective haplotype), and controls (no copies of either haplotype). (c) Adjacent
to the plot is the GLM incorporating the effects of sex, haplotype carrier status, affection status and age.
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ADHD subtype and type of stimulant medication
used for the treatment of ADHD symptoms (Supple-
mentary Table 6, Supplementary information). Sig-
nificant association, both at the marker (P < 0.05)
and haplotype (P < 0.01) level, was found for
response to stimulant medication and SNP marker
rs6551665 (which was also associated with ADHD)
(Figure 5b and c). In order to control for a possible
confounder effect of the LPHN3-associated SNPs to
ADHD in any pharmacogenetic protocol, we de-
signed an experiment looking for association be-
tween genotype and baseline SWAN scores to
dissect any effect correlated with specific symptom
dimensions of ADHD. Thus far, a quantity D quanti-
fying the change in the SWAN scale was defined as
follows:
For the question i and the individual j, we
calculated:
Di;j ¼ jQi;j;ON Qi;j;OFF j
i ¼ 1,2,y,18, j = 1,2,y,240,
which compares SWAN scale scores for all of the
questions in each individual when they were ON vs
OFF medication. Given Di,j we performed a Like-
lihood Ratio Test (LRT) between two models: Model
1: DBSexþAgeþGenotype, where Genotype refers
to G/G, G/A and A/A of rs6551665, being A/A the
reference genotype for comparisons, and Model 2:
DBSexþAge. The LRT discloses a significant improve-
ment of the model while including the genotype variable
(data not presented). To determine the significance and
direction of the Genotype effect, an ANOVA for Model 1
was conducted. Significant positive genotype effects
were identified for questions 2, 3 and 9 of the
Inattention component (Q2: F(2,160) = 4.96, P=0.008093;
Q3: F(2,160) =4.32, P=0.01487; Q9: F(2,160) =4.80,
P=0.009424) as well as for question number 18 of the
H/I component (Q18: F(2,160) =3.53, P=0.03167). We
concluded that genotypes with either one or two copies
of the G allele had a positive effect on D, and the
strongest response to medication.
A similar approach was used to quantify the
Genotype effect on both the Inattention and Hyper-
activity/Impulsivity (H/I) dimensions of the SWAN
scale. A Likelihood Ratio Test (LRT) between two
models: Model 1: DInattentionBSexþAgeþGenotype
Model 2: DInattentionBSexþAge, where DInattention =
|SInattention,ON–SInattention,OFF|, with SInattention,ON and
SInattention,OFF, are, respectively, the sum of the SWAN
scores for the Inattention questions (questions 1–9) ON
and OFF medication. Analogously, we performed an
LRT test to compare models with the same structure as
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Figure 5 (a) Profile plot of clusters derived from latent class cluster analyses applied to symptoms obtained by the SWAN
Scale for ADHD Symptoms screened while being OFF and ON medication. Attention deficit (Inattention) items abbreviated
for caption OFF medication (q1-q9): q1-careless, inattentive, q2-sustains attention poorly, q3-appears to not listen, q4-poor
follow through, q5-disorganized, q6-avoids/dislikes sustained mental effort, q7-loses needed objects, q8-easily distracted,
and q9-often forgetful. Hyperactivity/impulsivity items (q10–q18): q10-fidgets or squirms, q11-cannot stay seated, q12-
restless, q13-loud, noisy, q14-always ‘on the go’, q15-talks excessively, q16-blurts out, q178-impatient and q18-intrusive.
Similar sequence is followed for items while being ON medication, for example, (q1_med–q18_med). Age categories and sex
are also presented. Clusters 2, 4, 6 and 7 were defined as those where the stimulant treatment was effective. (b) Marker
and haplotype wise association analyses of variants associated to ADHD susceptibility to stimulant medication response.
(c) LD block containing the SNP rs6551665 and two additional surrogate markers, rs1947275 and rs9683662: OT: over
transmitted, T: Transmitted, U: not-transmitted.
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above but using DH/I=|SH/I,ONSH/I,OFF|. Here, SH/I,ON and
SH/I,OFF are, respectively, the sum of the SWAN scores for
the H/I questions (questions 10–18). Significant positive
genotype effects were identified for the Inattention
dimension (F(2,159) =3.71, P=0.02646) but not for the H/
I dimension (F(2,159) =2.41, P=0.09726).
Discussion
The research program that was initiated in 200214 and
produced intermediate results soon after15 was success-
ful in locating and characterizing a novel gene that
contributes to the genetic etiology of ADHD. The
unbiased linkage scan identified an ADHD susceptibility
region on chromosome 4.15,16 Here, we provide the
results of fine mapping that narrowed the region to the
coding sequence of LPHN3 (exons 4 through 19) that
contains important functional domains and most of the
splice isoform variability of the gene.
Iterative and expanded analyses of multiple gen-
erations of ADHD families from a genetic isolate in
Colombia provided a consistent and reliable presence
of association and linkage at the marker and haplo-
type level of LPHN3 variants. Association with ADHD
was replicated in US, German and Spanish families
and in a case–control analysis of a Norwegian sample.
The effect was larger in the Paisa sample than in
the samples used for replication. This may reflect
the unique characteristic of the Paisa isolate or the
method of ascertainment of the sample, which was from
families with a high prevalence of ADHD (about 30%)
and a subtype highly comorbid with conduct disorder
and substance use.4,16 The replicated association suggests
that regulation of LPHN3 expression may be involved in
the pathogenesis of ADHD. LPHN3 is a member of the
LPHN subfamily of G-protein-coupled receptors
(GPCRs). LPHNs have seven transmembrane regions as
well as long N-terminal extracellular sequences contain-
ing a 19-amino acid signal peptide (GPCR proteolytic
site, GPS domain), and a serine/threonine-rich glycosyla-
tion region50 (Figure 1d). LPHN1 and LPHN2 serve as
receptors for a-latrotoxin, a component of the venom
of the black widow spider (latrodectus mactans);
a-latrotoxin interacts with neuronal GPCRs to stimu-
late exocytosis of GABA-containing presynaptic
vesicles.51 LPHN3 is the most brain-specific LPHN50,52;
in fact, other GPCRs, such as DRD4 and DRD5, have been
associated directly with ADHD.53
The association of LPHN3 with increased risk
(ORB= 1.2) points to new neuro-molecular mechan-
isms related to ADHD. This increased risk appears
consistent with the role of LPHN3 in neuronal
transmission and maintenance of neuron viability.
In fact, the dosage of the LPHN3 susceptibility
haplotype varied inversely with the ratio of NAA/Cr,
a measure of the neuronal number thought to be
abnormal in ADHD. Moreover, mice lacking the
closely related LPHN1, although viable and fertile,
attend poorly to their offspring, resulting in increased
neonatal mortality.54
The interpretation of the 1.2 OR figure must be placed
in the context of its potential impact for the clinical and
epidemiological practice when dealing with ADHD in
the general population. We think that the Population
Attributable Risk (PAR), as a measure of epidemiological
impact, can provide a figure at a glance about the
consequences (prevalence and outcome) of an associa-
tion between an exposure factor (LPHN3 common
variant conferring susceptibility) and a disease (ADHD)
at the population level.55–57 Specifically, the PAR defines
the proportion of ADHD cases that could be treated if it
were possible to control for the effects of the LPHN3
common variant conferring susceptibility to ADHD. The
PAR is a function of the relative risk and the probability
of exposure (Pe) given that a person has the disease.
Because family-based samples provide OR instead of
relative risk, and for a highly prevalent disorder, such as
ADHD, the OR is not a good estimator of relative risk, we
calculated PAR% for marker rs65511665 with the case–
control-based sample from Norway, as proposed by
Hildebrandt et al.58 The 95% confidence intervals were
estimated as y^ z1a=2
ﬃﬃﬃﬃﬃﬃﬃﬃ
s^2
y^ ;B
q
where y^ is the PAR% point
estimation, z1–a/2 is the 1–a/2 quantile of the standard
normal distribution, and s^2
y^ ;B
is the simulation-based
variance of y^ given that B random samples are drawn. To
approach this variance, a total of B=100000 samples
were generated from a multinomial distribution as
proposed elsewhere.55,56 Thus far, the PAR% for the
marker rs6551665 in the Norway sample is 8.99 (95%
CI=3.90–14.12) meaning that by controlling the effect of
the LPHN3 common variant conferring susceptibility to
ADHD, a reduction of B9% in the ADHD incidence in
the Norway population would be observed. Though this
figure is encouraging, we anticipate that additional
population-based epidemiological studies would be
needed, as well as clinical and pharmacogenetic trials,
to confirm the impact of this gene in the general
population.
The spatial and temporal expression of LPHN3 also
supports its role in the pathogenesis of ADHD. LPHN3
is expressed in regions of the brain implicated in
ADHD (that is, the amygdala, caudate nucleus,
pontine nucleus and cerebellar Purkinje cells48) and
at earlier ages in human post-mortem brains59 (that is,
at a time in brain development when ADHD is
considered to emerge48).
It is very intriguing that the same variant (SNP
marker rs6551665) associated with susceptibility to
ADHD is also associated with response to stimulant
medication. This opens a window for the evaluation
of molecular substrates of ADHD and development of
new drugs targeting new genes and brain pathways
involved in ADHD.
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